• and subanalyses from the Phase III POLARIX study of Polivy ® (polatuzumab vedotin) in combination with Rituxan ® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). (biospace.com)
  • Alkylating agents , including chlorambucil (Leukeran) and cyclophosphamide (Cytoxan). (cancercare.org)
  • Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. (researcherprofiles.org)
  • Epcoritamab will either be studied as: - Monotherapy, or - Combination therapy: - epcoritamab + venetoclax - epcoritamab + lenalidomide - epcoritamab + R-CHOP (i.e., rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone). (researcherprofiles.org)
  • Currently, the standard treatment for newly diagnosed patients with CLL without adverse cytogenetic findings is a combination of fludarabine, cyclophosphamide, and rituxi- mab. (peptide-solubility.com)
  • This study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic Leukemia Study Group on first-line treatment with fludarabine plus cyclophosphamide, fludarabine, or chlorambucil. (haematologica.org)
  • Disease control in patients with two or more comorbidities was better with fludarabine plus cyclophosphamide than with fludarabine treatment, but not with fludarabine compared to chlorambucil treatment. (haematologica.org)
  • One of the first studies of Fludara in patients with recurrent CLL showed this agent to be better than the combination of cyclophosphamide, doxorubicin and prednisone (CAP). (broomeoncology.com)
  • A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia. (dukecancerinstitute.org)
  • Hands may produce one careful cleansing with reduction and cyclophosphamide, chlorambucil, busulfan. (techonepost.com)
  • For tumors resistant to radiation and for those animals unable to receive radiation therapy, systemic treatment with administration of chemotherapeutic agents, including melphalan, chlorambucil, cyclophosphamide, and glucocorticoids, have been recommended and have yielded long-term survival. (merckvetmanual.com)
  • In this interview, we discuss the results of the phase III MURANO trial, which tested the combination of venetoclax with rituximab in relapsed/refractory CLL. (cancernetwork.com)
  • The novel agent was again compared with rituximab at the 2013 American Society of Clinical Oncology meeting where, in combination with chlorambucil, the drug more than doubled the progression-free survival seen with chlorambucil monotherapy to 23 months versus 10.9 months. (medpagetoday.com)
  • A second main study involving 310 patients compared Calquence alone with a combination of other cancer medicines (rituximab and either idelalisib or bendamustine) in patients whose CLL had come back or not responded with previous treatment. (europa.eu)
  • After around 16 months, 17% of the patients given Calquence had died or their cancer had got worse, compared with 44% of those given the rituximab combinations. (europa.eu)
  • These patients usually can't tolerate aggressive chemotherapy, so the CLL11 study compared Leukeran (chlorambucil), an older chemotherapy, against Leukeran with Rituxan (rituximab), a current standard of care, or Leukeran with Gazyva (obinutuzumab), a recently approved therapy for newly diagnosed CLL. (curetoday.com)
  • The Appraisal Committee noted that the most likely incremental cost-effectiveness ratio (ICER) for Gazyvaro/chlorambucil compared with chlorambucil monotherapy was £31,000 per QALY gained, £28,000 per QALY gained compared with chlorambucil/MabThera (rituximab), £49,000 per QALY gained compared with bendamustine monotherapy, and £48,000 per QALY gained compared with bendamustine/MabThera, but it also said because of uncertainties these figures were likely to be higher. (pharmatimes.com)
  • Recent interim analysis of ibrutinib in combination with rituximab (IR) has demonstrated superior efficacy and a favorable safety profile versus R-FC [ 32 ]. (nature.com)
  • Idelalisib, in combination with rituximab, was approved for the treatment of patients with relapsed CLL for whom rituximab alone would be considered an appropriate therapy due to other comorbidities [ 22 ]. (biomedcentral.com)
  • To examine the usefulness of idelalisib in additional clinical scenarios, we conducted a pivotal phase 3, randomized, multicenter, double-blind, placebo-controlled trial of idelalisib, a phosphoinositol-3 kinase δ (PI3Kδ) inhibitor, in combination with bendamustine and rituximab, in patients with relapsed/refractory CLL (R/R CLL). (biomedcentral.com)
  • Some of the most often used active agents are chlorambucil and Fludara ® (fludarabine) and more recently, Rituxan ® (rituximab) and Campath ® (alemtuzumab). (broomeoncology.com)
  • Genentech) for use in combination with bendamustine, followed by obinutuzumab monotherapy, for the treatment of patients with follicular lymphoma whose disease relapsed after, or is refractory to, a regimen containing rituximab. (valuebasedrheumatology.com)
  • In ELEVATE-TN, results showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with either Calquence in combination with obinutuzumab or Calquence monotherapy versus chlorambucil chemotherapy plus obinutuzumab, a current standard-of-care combination used in the control arm. (centerwatch.com)
  • Approval was based on a clinical trial of 356 patients that showed significantly improved progression-free survival in patients treated with chemotherapy and obinutuzumab versus chemotherapy alone. (medpagetoday.com)
  • After a median of 65.4 months following treatment with Venclexta plus Gazyva, results confirm the combination continues to be an effective fixed-duration and chemotherapy-free option for patients with previously untreated CLL and coexisting conditions. (biospace.com)
  • Most of the newer, non-chemotherapy treatments, such as ibrutinib and other combinations of venetoclax are only available if you have relapsed from other treatment or cannot tolerate chemotherapy. (leukaemiacare.org.uk)
  • Although combination chemotherapy regimens, including the nucleoside analogue fludarabine, were once the most commonly used first-line therapy in CLL, non-chemotherapy regimens (eg, with Bruton tyrosine kinase [BTK] inhibitors) are currently preferred in most cases. (medscape.com)
  • The European Commission has granted marketing authorization to MabCampath® (alemtuzumab) for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate. (worldpharmanews.com)
  • With its demonstrated efficacy and manageable safety profile, MabCampath has the potential to become an important treatment option in Europe for patients with B-CLL for whom fludarabine combination chemotherapy is not appropriate. (worldpharmanews.com)
  • GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (CLL). (nature.com)
  • OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL). (physicianeditorial.com)
  • These drugs have produced long-term durable responses in the relapsed/refractory setting, and studies are underway using these as single agent upfront or in combination with both chemotherapy and monoclonal antibodies. (sagepub.com)
  • In contrast to microbial chemotherapy, there has been much greater emphasis on combination chemotherapy against cancer. (present5.com)
  • The objectives in combination chemotherapy have been to limit the toxicity of individual agents and to evade drug resistance by exposing the cancer cell to drugs with different modes of action simultaneously. (present5.com)
  • This FDA approval provides a new chemotherapy-free combination treatment option for patients, and underscores the growing utility of VENCLEXTA in CLL," said Michael Severino , M.D., vice chairman and president, AbbVie. (abbvie.com)
  • The approval of the VENCLEXTA combination means that patients with previously untreated CLL now have a finite duration, chemotherapy-free treatment option that can allow them to live longer without disease progression, induce high rates of minimal residual disease (MRD) negativity and, importantly, allow them to complete their course of therapy within 12 months. (abbvie.com)
  • Phase 3 Study of Sacituzumab Govitecan (IMMU-132) versus treatment of physicians´s choice (TPC) in subjects with hormonnal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer (MBC) who have failed at least two prior chemotherapy regimens. (sonnenscheinapotheke.de)
  • from any individual except oneself and solar radiation, and most of the leukaemia by a genotoxic mech- or an identical twin will provoke an chemical alkylating agents used in anism after its use in anticancer immune reaction against the graft- anticancer chemotherapy. (who.int)
  • Together, the trials showed that Calquence in combination with obinutuzumab or as a monotherapy significantly reduced the relative risk of disease progression or death versus the comparator arms in both 1st-line and relapsed or refractory CLL. (centerwatch.com)
  • Each can be used as a monotherapy (a drug used alone) or in combination with immunotherapy. (cancercare.org)
  • This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. (researcherprofiles.org)
  • That was a randomized trial of ibrutinib and venetoclax versus chlorambucil obinutzumab [Gazyva], and the data suggest, not surprisingly, that the small molecule combination is better. (cancernetwork.com)
  • WASHINGTON -- The FDA has approved obinutuzumab (Gazyva) as a combination treatment with chlorambucil for patients with untreated lymphocytic leukemia. (medpagetoday.com)
  • Updated results announced at the ASH conference found Gazyva significantly delayed progression-free survival over Rituxan (26.7 months versus 15.2 months). (curetoday.com)
  • Adding Gazyva also tripled complete responses compared with Rituxan (21 percent versus 7 percent). (curetoday.com)
  • Gazyva was the first drug with breakthrough therapy designation to receive FDA approval, on the back of trial data showing that, in combination with chlorambucil, it achieved progression free survival of an average of 23 months versus 11.1 months for patients taking the latter alone. (pharmatimes.com)
  • It is approved by the FDA as a first-line therapy for CLL, in combination with the immunotherapy obinutuzumab (Gazyva). (cancercare.org)
  • Gazyva is an important new medicine for people with newly diagnosed chronic lymphocytic leukemia as based on clinical data, it more than doubled the time people lived without their disease worsening compared to chlorambucil alone," said Hal Barron, M.D., chief medical officer and head of Global Product Development. (physicianeditorial.com)
  • Gazyva is now approved in combination with chlorambucil for people with previously untreated chronic lymphocytic leukemia (CLL) and is additionally being investigated in a large clinical programme, including multiple head-to-head Phase III studies compared to MabThera/Rituxan in indolent non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL). (physicianeditorial.com)
  • The pivotal Phase III CLL11 trial, conducted in cooperation with the German CLL Study Group (GCLLSG), is a multicentre, open-label, randomised three-arm study investigating the efficacy and safety profile of either Gazyva plus chlorambucil or MabThera/Rituxan plus chlorambucil compared to chlorambucil alone in 781 previously untreated people with CLL and co-existing medical conditions. (physicianeditorial.com)
  • Gazyva in combination with chlorambucil more than doubled the time people with newly diagnosed CLL lived without their disease getting worse (median PFS: 23.0 vs. 11.1 months). (physicianeditorial.com)
  • 75.9 percent of people responded to Gazyva in combination with chlorambucil (overall response rate, or ORR) compared to 32.1 percent with chlorambucil alone. (physicianeditorial.com)
  • Patients assigned to the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) had yet to reach median progression-free survival (PFS) after a median follow-up of 27 months, whereas the control regimen of obinutuzumab (Gazyva) and chlorambucil led to a median PFS of 21.0 months. (medpagetoday.com)
  • NORTH CHICAGO, Ill. , May 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (abbvie.com)
  • Results released this past summer found both combination regimens of Leukeran with the newer agents achieved better responses over Leukeran alone. (curetoday.com)
  • LEUKERAN (chlorambucil) can severely suppress bone marrow function. (nih.gov)
  • LEUKERAN (chlorambucil) was first synthesized by Everett et al. (nih.gov)
  • LEUKERAN (chlorambucil) is available in tablet form for oral administration. (nih.gov)
  • In a study of 12 patients given single oral doses of 0.2 mg/kg of LEUKERAN, the mean dose-adjusted (±SD) plasma chlorambucil C max was 492 ± 160 ng/mL, the AUC was 883 ± 329 ng.h/mL, the mean elimination half-life (t½) was 1.3 ± 0.5 hours, and the T max was 0.83 ± 0.53 hours. (nih.gov)
  • LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. (nih.gov)
  • Seventeen patients had received previous therapy, 6 of whom received fludarabine or fludarabine combinations. (pocketdrugguide.com)
  • Subsequently, we validated positive hits in vitro and in vivo using mice carrying BRCA2-deficient mammary tumors.Results: Three alkylators-chlorambucil, melphalan, and nimustine-displayed strong and specific toxicity against BRCA2-deficient cells. (figshare.com)
  • Our data call for the re-evaluation of alkylators, especially melphalan and nimustine, alone or in combination with the poly-(ADP-ribose)-polymerase inhibitors, for the treatment of breast cancers with a defective BRCA pathway. (figshare.com)
  • The study met its primary endpoint by demonstrating superior progression free survival (PFS) in patients treated with MabCampath versus chlorambucil, with MabCampath reducing the risk of disease progression or death by 42 percent (p=0.0001). (worldpharmanews.com)
  • the time from initiation of treatment until disease progression or death) in patients treated with VENCLEXTA plus obinutuzumab compared to patients who received chlorambucil plus obinutuzumab, a commonly used standard of care. (abbvie.com)
  • The efficacy assessment was based on 321 patients with relapsed or refractory follicular lymphoma who were randomized to obinutuzumab plus bendamustine followed by obinutuzumab alone versus bendamustine alone. (valuebasedrheumatology.com)
  • Currently, ibrutinib is taken daily until disease progression and venetoclax is also dosed once daily as part of a 12-cycle combination therapy. (medpagetoday.com)
  • The median time to progression (TTP) (median follow-up = 24 months) for the entire population was 25 months (median TTP in untreated patients had not yet been reached versus 18 months in treated patients). (pocketdrugguide.com)
  • In vitro, chlorambucil is 99% bound to plasma proteins, specifically albumin. (nih.gov)
  • In vitro drug combination experiments showed synergistic interactions between the alkylators and olaparib. (figshare.com)
  • 20 years ago to have in vitro activity against CLL cells by causing apoptosis by a unique mechanism. (peptide-solubility.com)
  • The clinical evidence for this NICE recommendation came mainly from the CLL14 clinical trial, which compared venetoclax and obinutuzumab against obinutuzumab plus chlorambucil. (leukaemiacare.org.uk)
  • This combination of venetoclax and obinutuzumab offers treatment option that is only taken for a fixed amount of time , which can be better tolerated and have fewer long term side effects that other treatments. (leukaemiacare.org.uk)
  • The only currently approved BH3-mimetic, the selective BCL2 inhibitor venetoclax, is highly efficacious in chronic lymphocytic leukemia and has rapidly advanced to an approved standard of care in frontline and relapsed disease in combination with anti-CD20 monoclonal antibodies. (biomedcentral.com)
  • Venetoclax combination with standard regimens in follicular lymphoma, multiple myeloma and aggressive B cell neoplasms has shown some promise, but further studies are required to optimize dose and scheduling to mitigate increased myelosuppression and infection risk, and to find validated biomarkers of venetoclax sensitivity. (biomedcentral.com)
  • Future research will focus on overcoming venetoclax resistance, targeting other BCL2 family members and the rational design of synergistic combinations. (biomedcentral.com)
  • Both ibrutinib and venetoclax have demonstrated efficacy as initial treatment for CLL, including a survival benefit with ibrutinib and a PFS benefit with venetoclax in combination with an anti-CD20 antibody. (medpagetoday.com)
  • However, Rituxan is more commonly used in combination therapy than as single agent therapy. (broomeoncology.com)
  • 0.0001) and lived significantly longer without their disease getting worse compared to those who received chlorambucil alone (median PFS 23.0 months vs. 11.1 months). (physicianeditorial.com)
  • 001). The median PFS was not reached with ibrutinib and was 18.9 months with chlorambucil (95% CI, 14.1-22.0). (valuebasedrheumatology.com)
  • The median survival was 35 months (median survival in the untreated group had not yet been reached versus 20 months in treated patients). (pocketdrugguide.com)
  • All newer agents have greater activity and more significant potential toxicity than chlorambucil, an agent that has been used for the treatment of CLL for decades. (peptide-solubility.com)
  • Lenalidomide,[10] an immune-modulating drug, has major activity against CLL but has not yet been approved primarily because of toxicity issues. (peptide-solubility.com)
  • Susan M. O'Brien, MD, highlights ongoing trials from 2021 examining combination therapies for patients with chronic lymphocytic leukemia. (cancernetwork.com)
  • The apparent volume of distribution averaged 0.31 L/kg following a single 0.2 mg/kg oral dose of chlorambucil in 11 cancer patients with chronic lymphocytic leukemia. (nih.gov)
  • The rolling submission of a Biologics License Application for the combination of ublituximab and umbralisib for the treatment of chronic lymphocytic leukemia has been completed for submission to the FDA. (targetedonc.com)
  • 1. TG Therapeutics completes rolling submission of Biologics License Application to the U.S. Food and Drug Administration for ublituximab in combination with uKONIQ™(umbralisib) as a treatment for patients with chronic lymphocytic leukemia. (targetedonc.com)
  • 2. 543 Umbralisib Plus ublituximab (U2) is Superior to obinutuzumab Plus chlorambucil (O+Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Results from the Phase 3 Unity-CLL Study. (targetedonc.com)
  • Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial. (sagepub.com)
  • Obinutuz-umab was previously approved in combination with chlorambucil for patients with treatment-naïve chronic lymphocytic leukemia. (valuebasedrheumatology.com)
  • An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia. (dukecancerinstitute.org)
  • Additionally, patients previously treated with obinutuzumab and/or chlorambucil or a PI3K delta inhibitor. (targetedonc.com)
  • Nivolumab, a cancer immunotherapy, is a checkpoint inhibitor that functions by blocking the programmed cell death 1 (PD-1)/programmed death ligand 1 pathway and restoring immunity against tumor cells ( 2 ). (cdc.gov)
  • One of the studies, involving 535 patients who had not had previous treatment for CLL, compared Calquence or its combination with obinutuzumab versus a combination of obinutuzumab with another cancer medicine, chlorambucil. (europa.eu)
  • Three studies investigated cyclosporin A (CSA) with or without prednisone versus prednisone or no treatment and one compared chlorambucil plus prednisone versus no treatment. (nih.gov)
  • Adult patients treated with CSA at an initial dose of 3.5-5 mg/kg/d in two divided doses perhaps in combination with oral prednisolone 0.15 mg/kg/d are more likely to achieve a partial remission of the nephrotic syndrome compared with symptomatic treatment or prednisolone alone. (nih.gov)
  • The combination was previously granted both a fast track designation and an orphan drug designation by the FDA for the treatment of adult patient patients with CLL. (targetedonc.com)
  • It is therefore important to identify alternative compounds that specifically target BRCA deficiency and to test new combination therapies to establish optimal treatment strategies.Experimental Design: We did a high-throughput pharmaceutical screen on BRCA2-deficient mouse mammary tumor cells and isogenic controls with restored BRCA2 function. (figshare.com)
  • This approval is based on the results from RESONATE-2, a randomized, multicenter, open-label phase 3 clinical trial, which compared ibrutinib with chlorambucil in 269 treatment-naïve patients (aged ≥65 years) with CLL or with small lymphocytic lymphoma. (valuebasedrheumatology.com)
  • A Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of orelabrutinib plus R-CHOP versus placebo plus R-CHOP in first-line treatment of patients with MCD subtype diffuse large B-cell lymphoma (DLBCL) is ongoing. (fixmyeuro.com)
  • Tafasitamab in combination with lenalidomide was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency for the treatment of eligible patients with relapsed or refractory (R/R) DLBCL. (fixmyeuro.com)
  • Tafasitamab in combination with lenalidomide was approved by the Health Commission and Medical Products Administration of Hainan Province , under the early access program in Boao Lecheng International Medical Tourism Pilot Zone for the treatment of eligible DLBCL patients. (fixmyeuro.com)
  • Urgent treatment to uterine relaxation, often asymptomatic or interfering with combination with the lateral humeral epiphysis. (techonepost.com)
  • The U.S. Food and Drug Administration today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations. (news-medical.net)
  • After around 28 months, 8% of the patients given Calquence in combination and 15% given Calquence alone had died or their cancer had got worse, compared with 53% given obinutuzumab and chlorambucil. (europa.eu)
  • We assume that hypocalcaemia in this case was promoted by a combination of hypoparathyroidism and bone metastasis. (bioscientifica.com)
  • V. Bone marrow and/or extranodal involvement. (dvm360.com)
  • The trial data also appears to suggest an overall survival benefit with RD. At the four-year follow-up, 59.4 percent of patients receiving continuous RD were alive compared with 51.4 percent receiving the MPT combination, but the difference is not significant, meaning the improvement in survival could be by chance. (curetoday.com)
  • Tumor intervention studies combining nimustine and olaparib resulted in recurrence-free survival exceeding 330 days in 3 of 5 animals tested.Conclusions: We generated and validated a platform for identification of compounds with specific activity against BRCA2-deficient cells that translates well to the preclinical setting. (figshare.com)
  • There was an increased incidence of venous and arterial thrombotic events in patients with multiple myeloma who received lenalidomide in combination with dexamethasone compared with dexamethasone alone in clinical trials. (pdr.net)
  • A subsequent GOG phase III study that was intended to compare pulse Act-D (1.25 mg/m 2 ) versus a multi-day (5-day or 8-day with folinic acid) MTX regimen was closed due to a low accrual rate (target 384, actual accrual 57). (medscape.com)
  • Here, we review standard upfront therapies and new agents and combinations that are on the horizon for CLL. (sagepub.com)
  • These drugs are often used in combination with a purine analog. (cancercare.org)
  • These rates in peripheral blood were 54.7% versus 39.0% ( P =0.0259). (medpagetoday.com)
  • 1 The FDA granted Breakthrough Therapy designation for this combination therapy, and early submission of the data was provided under the Real-Time Oncology Review (RTOR) pilot program, which led to approval in just over two months, following submission of the complete application. (abbvie.com)
  • High oral doses of alpha calcitriol and calcium with i.v. infusion of high calcium doses were instituted, altogether sufficient to maintain only mild hypocalcaemia. (bioscientifica.com)
  • After a single dose of radiolabeled chlorambucil ( 14 C), approximately 20% to 60% of the radioactivity appears in the urine after 24 hours. (nih.gov)
  • The decision by the European Commission to grant extended marketing authorization to MabCampath was based on data from the CAM307 study, an international open-label Phase III randomized trial comparing MabCampath with chlorambucil in previously untreated patients with B-CLL. (worldpharmanews.com)
  • This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of IGM-8444 as a single agent and in combination in subjects with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of IGM-8444+FOLFIRI (± bevacizumab). (researcherprofiles.org)
  • A trial published in 2003 investigated this combination in both treated and untreated patients of performance status 0,1, or 2. (pocketdrugguide.com)
  • It is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases. (nih.gov)
  • Chlorambucil, an aromatic nitrogen mustard derivative, is an alkylating agent. (nih.gov)
  • With this pathological finding, leuprolide (GNRH analogue) and chlorambucil (alkylating agent) were initiated, followed by prompt tapering of infused calcium down to full discontinuation. (bioscientifica.com)
  • Liposomal formulation of polyacrylate-peptide conjugate as a new vaccine candidate against cervical cancer. (jia-lab.com)
  • Chlorambucil is extensively metabolized in the liver primarily to phenylacetic acid mustard, which has antineoplastic activity. (nih.gov)
  • Again, less than 1% of the urinary radioactivity is in the form of chlorambucil or phenylacetic acid mustard. (nih.gov)
  • The approval also marks an important step in a long-term development plan that is exploring the full potential of MabCampath in high-risk CLL, combination and consolidation therapy. (worldpharmanews.com)
  • Single-agent therapy is given to palliate the disease (relieve symptoms) and improve the quality of life because toxicities are generally less severe than with combination therapy. (broomeoncology.com)
  • Pfizer) for use in combination with fulvestrant in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. (valuebasedrheumatology.com)
  • Chlorambucil interferes with DNA replication and induces cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bax, an apoptosis promoter. (nih.gov)